Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$7.09 +4.4%	$7.51	$5.90 ▼ $29.61	$498.51M	2.22	2.18 million shs	2.63 million shs
CGEM Cullinan Therapeutics	$7.64 +5.1%	$7.96	$6.85 ▼ $19.89	$429.47M	-0.08	333,197 shs	365,458 shs
CLYM Climb Bio	$1.63 +1.2%	$1.39	$1.05 ▼ $8.79	$108.80M	-0.11	531,535 shs	383,270 shs
GOSS Gossamer Bio	$1.97 +2.1%	$1.55	$0.66 ▼ $2.23	$438.85M	1.96	3.55 million shs	2.94 million shs

10 Stocks Set to Soar in Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	+3.03%	-10.78%	-12.84%	+11.86%	-72.35%
CGEM Cullinan Therapeutics	+2.54%	-10.02%	-5.58%	+1.96%	-55.40%
CLYM Climb Bio	-2.42%	-7.47%	+17.52%	+37.61%	+160,999,900.00%
GOSS Gossamer Bio	+11.37%	-10.65%	+41.91%	+91.09%	+142.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARVN Arvinas	3.6916 of 5 stars	4.3	2.0	0.0	2.8	2.5	1.3
CGEM Cullinan Therapeutics	1.8322 of 5 stars	3.5	1.0	0.0	1.5	1.7	0.6
CLYM Climb Bio	3.5202 of 5 stars	3.6	0.0	0.0	3.8	2.5	1.3
GOSS Gossamer Bio	3.8789 of 5 stars	3.5	1.0	4.7	3.1	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARVN Arvinas	2.55	Moderate Buy	$19.76	178.75% Upside
CGEM Cullinan Therapeutics	3.00	Buy	$30.00	292.67% Upside
CLYM Climb Bio	3.25	Buy	$9.00	452.15% Upside
GOSS Gossamer Bio	3.00	Buy	$8.50	331.47% Upside

Current Analyst Ratings Breakdown

Latest CLYM, ARVN, CGEM, and GOSS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	ARVN Arvinas	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $18.00
8/7/2025	ARVN Arvinas	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$19.00 ➝ $16.00
8/7/2025	ARVN Arvinas	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
8/6/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $5.00
7/14/2025	GOSS Gossamer Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$11.00
6/11/2025	CGEM Cullinan Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$22.00
6/6/2025	CLYM Climb Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
6/2/2025	ARVN Arvinas	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$24.00
6/2/2025	ARVN Arvinas	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$10.00 ➝ $9.00
6/1/2025	ARVN Arvinas	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/22/2025	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARVN Arvinas	$372.80M	1.40	N/A	N/A	$8.30 per share	0.85
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$8.33 per share	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.15 per share	N/A
GOSS Gossamer Bio	$114.70M	3.91	N/A	N/A	($0.20) per share	-9.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARVN Arvinas	-$198.90M	-$1.01	N/A	N/A	N/A	-19.47%	-12.01%	-6.97%	10/29/2025 (Estimated)
CGEM Cullinan Therapeutics	-$167.38M	-$3.23	N/A	N/A	N/A	N/A	-36.56%	-34.82%	8/14/2025 (Estimated)
CLYM Climb Bio	-$73.90M	-$0.70	N/A	N/A	N/A	N/A	-43.95%	-42.94%	N/A
GOSS Gossamer Bio	-$56.53M	-$0.62	N/A	N/A	N/A	-344.81%	-1,774.72%	-46.73%	N/A

Latest CLYM, ARVN, CGEM, and GOSS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CLYM Climb Bio	-$0.19	-$0.13	+$0.06	-$0.13	N/A	N/A
8/7/2025	Q2 2025	CGEM Cullinan Therapeutics	-$0.83	-$1.07	-$0.24	-$1.07	N/A	N/A
8/6/2025	Q2 2025	ARVN Arvinas	-$0.87	-$0.84	+$0.03	-$0.84	$34.42 million	$22.40 million
8/5/2025	Q2 2025	GOSS Gossamer Bio	-$0.18	-$0.17	+$0.01	-$0.17	$4.12 million	$11.49 million
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million
5/14/2025	Q1 2025	CLYM Climb Bio	-$0.15	-$0.31	-$0.16	-$0.31	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARVN Arvinas	N/A	5.64	5.64
CGEM Cullinan Therapeutics	N/A	9.83	9.83
CLYM Climb Bio	N/A	14.25	14.25
GOSS Gossamer Bio	6.70	4.40	4.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARVN Arvinas	95.19%
CGEM Cullinan Therapeutics	86.31%
CLYM Climb Bio	69.76%
GOSS Gossamer Bio	81.23%

Insider Ownership

Company	Insider Ownership
ARVN Arvinas	4.73%
CGEM Cullinan Therapeutics	6.07%
CLYM Climb Bio	0.80%
GOSS Gossamer Bio	6.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARVN Arvinas	420	73.42 million	69.95 million	Optionable
CGEM Cullinan Therapeutics	30	59.07 million	55.49 million	Optionable
CLYM Climb Bio	9	67.58 million	65.41 million	N/A
GOSS Gossamer Bio	180	227.38 million	212.15 million	Optionable

CLYM, ARVN, CGEM, and GOSS Headlines

Recent News About These Companies

Gossamer Bio Reports Q2 2025 Financial Results

August 12 at 5:24 AM | msn.com

Gossamer Bio (NASDAQ:GOSS) Cut to Sell at Wall Street Zen

August 12 at 3:01 AM | americanbankingnews.com

Wedbush Brokers Increase Earnings Estimates for Gossamer Bio

August 12 at 2:03 AM | americanbankingnews.com

Institutional investors in Gossamer Bio, Inc. (NASDAQ:GOSS) see US$54m decrease in market cap last week, although long-term gains have benefitted them.

August 11 at 12:23 AM | finance.yahoo.com

HC Wainwright Has Positive View of Gossamer Bio Q3 Earnings

August 11 at 2:01 AM | americanbankingnews.com

Q3 EPS Estimates for Gossamer Bio Increased by HC Wainwright

August 11 at 2:59 AM | marketbeat.com

Wedbush Has Optimistic Outlook of Gossamer Bio Q3 Earnings

August 11 at 2:59 AM | marketbeat.com

Gossamer Bio (NASDAQ:GOSS) Stock Rating Lowered by Wall Street Zen

August 10 at 2:19 AM | marketbeat.com

Leerink Partners Sticks to Its Buy Rating for Gossamer Bio (GOSS)

August 9, 2025 | theglobeandmail.com

Q3 EPS Estimates for Gossamer Bio Reduced by Leerink Partnrs

August 9, 2025 | marketbeat.com

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 7, 2025 | businesswire.com

Wedbush Boosts Gossamer Bio (NASDAQ:GOSS) Price Target to $5.00

August 7, 2025 | marketbeat.com

FY2025 EPS Estimates for Gossamer Bio Boosted by Analyst

August 7, 2025 | marketbeat.com

FY2025 EPS Estimates for Gossamer Bio Increased by Analyst

August 7, 2025 | americanbankingnews.com

Gossamer Bio (NASDAQ:GOSS) Issues Earnings Results, Beats Expectations By $0.01 EPS

August 6, 2025 | marketbeat.com

Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update

August 5, 2025 | bakersfield.comB

Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates

August 5, 2025 | zacks.com

Gossamer Bio (GOSS) Expected to Announce Quarterly Earnings on Monday

August 5, 2025 | marketbeat.com

Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Sold by GSA Capital Partners LLP

August 3, 2025 | marketbeat.com

Scotiabank Initiates Outperform on Gossamer Bio (GOSS) with an $11 PT, Highlights Potential of PAH Drug Seralutinib

August 1, 2025 | insidermonkey.com

Investors Purchase High Volume of Call Options on Gossamer Bio (NASDAQ:GOSS)

July 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLYM, ARVN, CGEM, and GOSS Company Descriptions

Arvinas NASDAQ:ARVN

$7.09 +0.30 (+4.42%)

Closing price 04:00 PM Eastern

Extended Trading

$7.04 -0.05 (-0.71%)

As of 07:52 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Cullinan Therapeutics NASDAQ:CGEM

$7.64 +0.37 (+5.09%)

Closing price 04:00 PM Eastern

Extended Trading

$7.64 0.00 (0.00%)

As of 06:51 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Climb Bio NASDAQ:CLYM

$1.63 +0.02 (+1.24%)

As of 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Gossamer Bio NASDAQ:GOSS

$1.97 +0.04 (+2.07%)

Closing price 04:00 PM Eastern

Extended Trading

$2.00 +0.03 (+1.52%)

As of 07:53 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time